Cholecystokinin 2 receptor targeted NIR imaging and use thereof
Inventors
Kularatne, Sumith A. • Gagare, Pravin • Noshi, Mohammad
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Compounds are described herein where CCK2R targeting ligands are attached to an imaging agent through a linker. The compounds can be used in the detection, diagnosis, imaging and treatment of cancer.
Core Innovation
The invention relates to a compound having the formula B-L-Z, where B is a targeting ligand capable of selectively binding to CCK2R and/or CCK2i4svR. The compound includes L as a linker selected from the group consisting of glutamic acid, and Z as an imaging agent represented by a defined formula with substituent groups R1, R2, and R3, R4, and R5, or salts thereof, or isotopes thereof.
In the compound, the values of m and n are independently selected from 0, 1, or 2, and L is stated to enhance the binding affinity and biodistribution of the compound. Z is described as an imaging agent in connection with optical imaging, including near-infrared excitation light, and the disclosed compounds are capable of fluorescence after distributed in tissue.
The invention also relates to therapeutic use in cancer-bearing subjects by administering the disclosed compound, including human and animal subjects, to produce a therapeutic effect on tissue/cells. The disclosed tumor indications include kidney cancers, medullary thyroid cancers, insulinomas, small cell lung cancers, bronchial and ileal carcinoids, GIST tumors, colon cancers, hepatocellular carcinomas, pancreatic cancers, and stomach cancer, with target cells expressing the CCK2 receptor.
Claims Coverage
The independent claim is directed to the chemical compound formula B-L-Z with a CCK2R/CCK2i4svR-binding targeting ligand, a glutamic acid linker, and a defined optical imaging agent Z, with L enhancing binding affinity and biodistribution. Four inventive features are present in the merged claim coverage, with additional selected ranges for m and n and defined imaging-agent substituent groups, plus optional pharmaceutically acceptable salt and isotope embodiments.
Targeting ligand selectively binding to CCK2R and/or CCK2i4svR
A targeting ligand B capable of selectively binding to CCK2R and/or CCK2i4svR, in the compound having the formula B-L-Z.
Linker is glutamic acid enhancing binding affinity and biodistribution
L is a linker selected from the group consisting of glutamic acid, and L is stated to enhance the binding affinity and biodistribution of the compound.
Imaging agent Z defined by substituent groups with optional salts or isotopes
Z is an imaging agent represented by a formula in which R1 is independently selected from O, S, N and C; R2 is independently selected from CH2 and CH2CH2CH2; and each of R3, R4, and R5 is independently selected from H, Na, K, and NH4 or a salt thereof, or isotopes thereof.
m and n selected from 0, 1, or 2
Values of m and n are independently selected from the values 0, 1, or 2 in the compound formula B-L-Z.
Across the disclosed claim set, the central coverage is the compound architecture B-L-Z with CCK2R/CCK2i4svR-selective targeting, a glutamic acid linker that enhances binding affinity and biodistribution, and an optical imaging agent Z defined by specific substituent selections, with optional pharmaceutically acceptable salt and isotope embodiments.
Stated Advantages
L enhances binding affinity and biodistribution of the compound.
The compound enables optical imaging of cancer using Z as an optical imaging agent.
The disclosed compounds are capable of fluorescence after distributed in tissue and are adapted to fluoresce upon near-infrared excitation light.
Documented Applications
Imaging cancer and detecting/diagnosing cancer in connection with a kit using Z as an optical imaging agent.
Use for imaging tumor/cancer types including kidney cancers, medullary thyroid cancers, insulinomas, small cell lung cancers, bronchial and ileal carcinoids, GIST tumors, colon cancers, hepatocellular carcinomas, pancreatic cancers, and stomach cancer.
Therapeutic use in cancer-bearing subjects (human/animal) by administering the compound to produce a therapeutic effect.
Interested in licensing this patent?